Effective price per mg uses an active dated override first, then the row-level historical discount, then the vendor default from the same Git revision. Aggregate chart points include exact-comparability offers only. Missing observations remain gaps; the series does not interpolate across unavailable offers or absent snapshots.

Price watch · beta

Let the market come to you.

Watch the best market price or one vendor. Get one email when Oxytocin crosses your target, drops, or sets a new tracked low—without daily noise.

Price scope Alert me Target per mg

$/mg

Confirmed Weekly Peptide Intel email

Requires a confirmed Weekly Peptide Intel address, then a separate alert confirmation. Already watching? Manage price alerts. Public prices can change; confirm the final cart total.

Public product evidence 52 certificate records for Oxytocin products, from 33 vendors 27 reference a report on the testing laboratory's own system · 27 have a laboratory lookup that answered when last checked · 46 match a vendor product page at the same address

Status

FDA Approved

This peptide maps to at least one regulated medical product or label context in the United States.

Research area

Hormone signaling research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Aliases

Pitocin

Signal depth

High

FDA label signal · 1403 trials · 29460 PubMed results

Established

Research evidence

Oxytocin is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Oxytocin has 55 name-matched clinical trials (3 international) (highest phase: Phase 4) and 29460 PubMed-indexed publications and holds an FDA drug label. 15 trials have posted results.

🌍 3 international trials FAERS (approved drug): 2,735

Human data

Approved drug

Trial quality

Large RCT

Outcomes

Clinical outcomes

Replication

Meta-analysis

Literature

Top-tier journals

PHASE4 · Randomized Reducing Neonatal Morbidity by Discontinuing Oxytocin During the Active Phase of 1st Stage of Labor PHASE4 · Randomized IV Versus IM Administration of Oxytocin for Postpartum Bleeding PHASE4 · Randomized Oxytocin Infusion vs. Spontaneous Follow-up for Third-stage of Labor After Second-trimester Abortion ISRCTN Comparing different concentrations of oxytocin to augment slow labour in obese mothers ISRCTN Oxytocin injection and misoprostol tablet compared to oxytocin-ergometrine injection and placebo tablet to prevent bleeding after vaginal delivery Nature · 3,708 citations Oxytocin increases trust in humans

Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-10-03 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What oxytocin is

Oxytocin is a naturally occurring peptide hormone with established medical use in regulated clinical settings. It is also one of the few hormone peptides that people may recognize outside peptide-market culture.

Why it matters

It anchors the hormone category with a peptide that has legitimate clinical history rather than only research-market visibility.

Regulatory context

Oxytocin is associated with FDA-approved medical products and clinical use. That does not make every non-medical or retail framing of oxytocin equivalent to an approved use case.

Practical reading note

This is another case where the ingredient name alone is not enough. Formulation, indication, and clinical context matter.